drugset
drugset / Trial / NCT04747808

Study of LL-BMT1 in Patients With Elevated Intraocular Pressure

NCT04747808 ↗

Phase 2 Completed 5 enrolled MediPrint Ophthalmics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label, Phase 2a clinical study of LL-BMT1 in patients with primary open-angle glaucoma and ocular hypertension. Study subjects will be treated for 7 days with a single dose of LL-BMT1.

Timeline

Start
2021-01-08
Primary completion
2021-02-16
Completion
2021-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimatoprost Other / unclassified — Other

Indications

ocular hypertension open-angle glaucoma